Biagio Ricciuti, MD, Looks Toward Future Research in NSCLC Involving PD-L1 Expression


Biagio Ricciuti, MD, spoke about future analyses and major takeaways of a study analyzing outcomes with frontline immunotherapy based on PD-L1 expression in patients with non–small cell lung cancer.

At the 2022 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Biagio Ricciuti, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, about future research into efficacy of pembrolizumab (Keytruda) monotherapy in patients with non–small cell lung cancer (NSCLC) who have PD-L1 tumor proportion scores (TPS) of 90% or more. At the conference, he and his fellow authors presented data from a study which looked at prolonged benefit of the agent at 3 years for patients with a high PD-L1 expression of 90% or more.

At the median follow-up of 42.6 months, treatment benefit included a median progression-free survival of 5.1 months and median overall survival of 19.0 months in all patients with PD-L1 expression above 50%. For patients who had PD-L1 TPS of 90% or more, median PFS was 6.0 months vs 4.5 months with PD-L1 TPS of 50% to 89% (HR, 0.67; P <.001). Corresponding median OS was 30.2 months vs 16.9 months (HR, 0.66; P <.01).


We now are in the phase of gathering additional data, and we did some more qualitative analyses. Specifically, we will try to enlarge the cohort of [patients with] NSCLC who will be profiled with multiplex immunofluorescence so that we can validate our findings. We also were planning to include more samples for [genomic] profiling so that we can validate the mutations that are found in high vs very high PD-L1 expressors. As part of the study, we will also try to explore whether there are any differences in safety between the 2 groups. There are other scientists that are currently working on this.

The most important takeaway from this analysis is that among patients with NSCLC and PD-L1 expression of 50% or greater who have highly altered genes, we shouldn’t consider this patient population as a single group of patients but [rather as a] more heterogeneous group with different immunophenotypic features which may depend on the PD-L1 expression. In addition to this, important data [reveal] that patients with very high expression at 3 years kept experiencing prolonged benefits from immunotherapy. These patients are more likely to complete the treatment cycles of anti–PD-1 monotherapy [to 2 years]. Because of this, we may individualize treatment based on very high PD-L1 expression when we have to decide whether we want to prescribe a first-line [treatment], which is a monotherapy vs a chemoimmunotherapy combination. In this setting, this information might be helpful to guide through the transition.


Ricciuti B, Elkrief A, Alessi J, et al. Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab. J Clin Oncol. 2022;40(suppl 16):9043. doi: 10.1200/JCO.2022.40.16_suppl.9043

Related Videos
Cell therapy and vaccine approaches are among the several potential options for targeting KRAS in patients with KRAS G12C–mutated non–small cell lung cancer, says Sandip P. Patel, MD.
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Sandip P. Patel, MD, an expert on lung cancer
Sandip P. Patel, MD, an expert on lung cancer
Related Content